Theravance Biopharma (TBPH) to Release Quarterly Earnings on Thursday

Theravance Biopharma (NASDAQ:TBPH – Get Rating) will issue its quarterly earnings data after the market closes on Thursday, May 5th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Theravance Biopharma (NASDAQ:TBPH – Get Rating) last issued its earnings results on Wednesday, February 23rd. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.13). The firm had revenue of $14.95 million during the quarter, compared to analyst estimates of $15.59 million. During the same quarter in the previous year, the business earned ($0.92) earnings per share. On average, analysts expect Theravance Biopharma to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Shares of NASDAQ TBPH traded up $0.20 during midday trading on Tuesday, hitting $10.39. 4,690 shares of the company’s stock were exchanged, compared to its average volume of 520,643. Theravance Biopharma has a twelve month low of $6.10 and a twelve month high of $20.27. The company has a market cap of $788.60 million, a P/E ratio of -3.45 and a beta of 0.78. The firm has a fifty day simple moving average of $9.77.

Several hedge funds have recently made changes to their positions in the business. Norges Bank purchased a new position in shares of Theravance Biopharma in the 4th quarter valued at approximately $5,891,000. Deutsche Bank AG grew its stake in shares of Theravance Biopharma by 14.4% in the 4th quarter. Deutsche Bank AG now owns 45,869 shares of the biopharmaceutical company’s stock valued at $507,000 after purchasing an additional 5,768 shares during the last quarter. California State Teachers Retirement System grew its stake in shares of Theravance Biopharma by 4.8% in the 4th quarter. California State Teachers Retirement System now owns 79,054 shares of the biopharmaceutical company’s stock valued at $874,000 after purchasing an additional 3,614 shares during the last quarter. Parametric Portfolio Associates LLC grew its stake in shares of Theravance Biopharma by 64.6% in the 4th quarter. Parametric Portfolio Associates LLC now owns 74,606 shares of the biopharmaceutical company’s stock valued at $824,000 after purchasing an additional 29,278 shares during the last quarter. Finally, Legal & General Group Plc grew its stake in shares of Theravance Biopharma by 34.3% in the 4th quarter. Legal & General Group Plc now owns 57,397 shares of the biopharmaceutical company’s stock valued at $634,000 after purchasing an additional 14,648 shares during the last quarter. Institutional investors own 78.14% of the company’s stock.

TBPH has been the topic of several research analyst reports. StockNews.com initiated coverage on Theravance Biopharma in a research report on Thursday, March 31st. They set a “hold” rating on the stock. Morgan Stanley raised their price target on Theravance Biopharma from $10.00 to $11.00 and gave the stock an “underweight” rating in a research note on Wednesday, March 2nd. Finally, HC Wainwright raised their price target on Theravance Biopharma from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, February 24th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $11.06.

Theravance Biopharma Company Profile (Get Rating)

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

Featured Stories